KIMS Q1 FY26 consolidated profit slips to Rs. 78.6 Cr

KIMS has reported total income of Rs. 878.7 crores during the period ended June 30, 2025

Zydus receives final approval from USFDA for Prucalopride Tablets

Prucalopride is prescribed for chronic idiopathic constipation

Suraksha Diagnostic reports Q1 FY26 PAT higher by 20% at Rs. 9.1 Cr

WACKER and Gearbox Biosciences collaborate to advance pDNA manufacturing technologies

The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines

Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr

Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025

IOL Chemicals post Q1 FY26 consolidated profit at Rs. 33.93 Cr

IOLCP has reported total income of Rs. 559.06 crores during the period ended June 30, 2025

ZIM Laboratories granted marketing authorization for Tamsulosin + Dutasteride capsules in Australia

Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men

Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 &1 mg

This is the group’s first NoC approval in Canada

Indegene posts Q1 net profit higher by 33% YoY to Rs. 116.4 Cr

The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore

AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients

The submission is supported by positive results from the Phase 3 AMPLIFY trial